Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

produce immune interferon in response
to antigen or mitogen. J Exp
Med 1982; 155: 1198±203.
92 Filgueira L, Zuber M, Juretic A,
Luscher U, Caetano V, Harder F,
Garotta G, Heberer M, Spagnoli GC.
Differential effects of interleukin-2 and
CD3 triggering on cytokine gene transcription
and secretion in cultured tumor
infiltrating lymphocytes. Cell Immunol
1993; 150: 205±18.
93 Bennett SR, Carbone FR, Karamalis
F, Flavell RA, Miller JF,
Heath WR. Help for cytotoxic-T-cell responses
is mediated by CD40 signalling.
Nature 1998; 393: 478±80.
94 Reid CD. The biology and clinical applications
of dendritic cells. Transfus
Med 1998; 8: 77±86.
95 Ridge JP, Di Rosa F, Matzinger P.
A conditioned dendritic cell can be a
temporal bridge between a CD4 + Thelper
and a T-killer cell. Nature 1998;
393: 474±8.
96 Schoenberger SP, Toes RE, van der
Voort EI, Offringa R, Melief CJ.
T-cell help for cytotoxic T lymphocytes
is mediated by CD40±CD40L interactions.
Nature 1998; 393: 480±3.
97 Lanzavecchia A. Licence to kill. Nature
1998; 393: 413±4.
98 Siegel JP. Effects of interferon-g on the
activation of human T lymphocytes.
Cell Immunol 1988; 111: 461±72.
99 Tuttle TM, McCrady CW, Inge TH,
Salour M, Bear HD. g-Interferon plays
a key role in T-cell-induced tumor regression.
Cancer Res 1993; 53: 833±9.
100 Talmadge JE. Therapeutic potential of
cytokines: a comparison of preclinical
and clinical studies. Prog Exp Tumor Res
1988; 32: 154±73.
101 Takeshita T, Asao H, Ohtani K,
Ishii N, Kumaki S, Tanaka N, Munakata
H, Nakamura M, Sugamura K.
Cloning of the gamma chain of the human
IL-2 receptor. Science 1992; 257:
379±82.
102 Smith KA. Lowest dose interleukin-2
immunotherapy. Blood 1993; 81: 1414±
23.
103 Stuhler G, Schlossman SF. Antigen
organization regulates cluster formation
and induction of cytotoxic T lym-
References
phocytes by helper T cell subsets. Proc
Natl Acad Sci USA 1997; 94: 622±7.
104 Stuhler G, Zobywalski A, Grunebach
F, Brossart P, Reichardt VL,
Barth H, Stevanovic S, Brugger W,
Kanz L, Schlossman SF. Immune regulatory
loops determine productive interactions
within human T lymphocytedendritic
cell clusters. Proc Natl Acad
Sci USA 1999; 96: 1532±5.
105 Pawelec G, Rees RC, Kiessling R, Madrigal
A, Dodi A, Baxevanis C, Gambacorti-Passerini
C, Masucci G,
Zeuthen J. Cells and cytokines in immunotherapy
and gene therapy of cancer.
Crit Rev Oncogenes 1999; 10: 83±
127.
106 Banchereau J, Steinman RM. Dendritic
cells and the control of immunity.
Nature 1998; 392: 245±52.
107 Shortman K, Caux C. Dendritic cell
development: multiple pathways to nature's
adjuvants. Stem Cells 1997; 15:
409±19.
108 Porgador A, Gilboa E. Bone marrowgenerated
dendritic cells pulsed with a
class I-restricted peptide are potent inducers
of cytotoxic T lymphocytes. J
Exp Med 1995; 182: 255±60.
109 Urban JL, Schreiber H. Host±tumor
interactions in immunosurveillance
against cancer. Prog Exp Tumor Res
1988; 32: 17±68.
110 Berd D, Maguire HC Jr, McCue P,
Mastrangelo MJ. Treatment of metastatic
melanoma with an autologous tumor-cell
vaccine: clinical and immunologic
results in 64 patients. J Clin Oncol
1990; 8: 1858±67.
111 Morton DL, Foshag LJ, Hoon DS,
Nizze JA, Famatiga E,Wanek LA,
Chang C, Davtyan DG, Gupta RK,
Elashoff R, Irie RF. Prolongation of
survival in metastatic melanoma after
active specific immunotherapy with a
new polyvalent melanoma vaccine. Ann
Surg 1992; 216: 463±82.
112 Morton DL, Barth A. Vaccine therapy
for malignant melanoma. CA Cancer
J Clin 1996; 46: 225±44.
113 Crowley NJ, Slingluff CL Jr, Darrow
TL, Seigler HF. Generation of human
autologous melanoma-specific cytotoxic
T-cells using HLA-A2-matched allo-
247